PPIG Antibody

What is PPIG and why is it relevant to research?

PPIG (Peptidyl-prolyl cis-trans isomerase G) is a protein that belongs to the peptidyl-prolyl isomerase family. According to current research, PPIG performs several critical cellular functions:

• Accelerates protein folding by catalyzing the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

• Plays a role in protein folding, transport, and assembly

• Contributes significantly to the regulation of pre-mRNA splicing

PPIG is ubiquitously expressed and primarily localizes to the nuclear matrix . Its involvement in fundamental cellular processes like RNA processing and protein folding makes it a valuable target for investigations into cellular mechanisms and potential disease pathways where these processes may be dysregulated.

The species reactivity of PPIG antibodies varies across manufacturers, with most showing strong reactivity to human PPIG:

When selecting a PPIG antibody for cross-species studies, it's important to verify that the antibody has been validated for your specific target species. The cross-reactivity observed with mouse and rat is likely due to high sequence conservation of PPIG across these mammalian species .

What is the optimal storage and handling protocol for PPIG antibodies?

Based on manufacturer recommendations, PPIG antibodies require specific storage conditions to maintain optimal activity:

• Long-term storage: Store at -20°C (typical shelf life of 12 months from date of receipt)

• Short-term storage: For frequent use, store at 4°C for up to one month

• Aliquoting: Divide into small aliquots upon receipt to minimize freeze-thaw cycles

• Reconstitution (for lyophilized antibodies): Follow manufacturer-specific instructions (typically with sterile dH₂O to a final concentration of 500 μg/ml)

• Freeze-thaw cycles: Minimize repeated freezing and thawing as this can denature and reduce antibody activity

For lyophilized PPIG antibodies, one manufacturer specifies reconstitution with 0.2 mL sterile dH₂O to achieve a 500 μg/ml final concentration , though specific instructions may vary between suppliers.

What molecular weight should PPIG appear at in Western blot analysis?

Researchers should note that the observed molecular weight of PPIG in Western blots differs from the calculated molecular weight:

• Observed molecular weight: Consistently reported as 110 kDa

• Calculated molecular weight: 88 kDa or 88,617 Da

This discrepancy between calculated and observed molecular weights (approximately 22 kDa difference) likely results from post-translational modifications or structural properties that affect protein migration in SDS-PAGE gels. When performing Western blot analysis of PPIG, researchers should expect to observe a band at approximately 110 kDa, though slight variations may occur depending on tissue type, cell line, or experimental conditions.

How can phospho-specific PPIG antibodies advance studies of post-translational regulation?

Phospho-specific PPIG antibodies, such as those targeting phosphorylation at Ser376 , provide valuable tools for studying post-translational regulation:

Methodological approaches:

• Signaling pathway analysis: Treat cells with pathway activators or inhibitors and monitor changes in PPIG phosphorylation to identify regulatory networks.

• Kinase identification: The phosphorylation of Ser376 on PPIG was identified as a consensus site for ACG kinase , suggesting experiments with ACG kinase inhibitors could help confirm this regulatory mechanism.

• Phosphorylation dynamics: Phospho-specific antibodies enable temporal studies of PPIG phosphorylation in response to cellular stimuli.

• Quantitative analysis: Run parallel Western blots with both total PPIG antibody and phospho-specific antibody to calculate the phosphorylated-to-total PPIG ratio.

• Validation controls: Include phosphatase-treated samples as negative controls to verify phospho-antibody specificity.

Experimental design should incorporate appropriate controls, including phosphatase-treated samples and stimulation conditions known to affect the specific phosphorylation site under investigation.

What challenges exist in validating PPIG antibodies for research applications?

Several methodological challenges must be addressed when validating PPIG antibodies:

• Antibody specificity: Ensuring the antibody specifically recognizes PPIG without cross-reacting with other cyclophilin family members or structurally similar proteins.

• Application-specific performance: Antibodies validated for Western blot may not perform equivalently in immunoprecipitation or immunohistochemistry applications. Each application requires independent validation.

• Epitope accessibility: For applications using non-denatured protein (immunoprecipitation, flow cytometry), the epitope recognized by the antibody must be accessible in the native conformation.

• Control selection: Appropriate positive and negative controls are essential, including:

  • PPIG-overexpressing cells

  • PPIG knockout/knockdown cells

  • Blocking peptides corresponding to the immunogen

• Post-translational modifications: Since PPIG undergoes phosphorylation at sites like Ser376 , these modifications may affect antibody recognition depending on the epitope location.

• Lot-to-lot variation: Particularly with polyclonal antibodies, significant variation can occur between production lots, necessitating validation of each new lot.

Researchers should implement a comprehensive validation strategy using multiple methodological approaches to ensure antibody specificity and reliability.

What are the optimal protocols for PPIG antibody use in immunohistochemistry?

For immunohistochemical studies of PPIG, the following protocol incorporates manufacturer recommendations and standard IHC methodologies:

Sample preparation:

• Fix tissue sections in 10% neutral buffered formalin

• Embed in paraffin and section at 4-6 μm thickness

• Mount sections on positively charged slides

Antigen retrieval and staining:

• Deparaffinize and rehydrate sections through graded alcohols

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Block endogenous peroxidase with 3% hydrogen peroxide

• Apply protein block to reduce non-specific binding

• Incubate with primary PPIG antibody at manufacturer-recommended dilution (typically 1:500-1:1000)

• Apply appropriate detection system (HRP-polymer or secondary antibody)

• Develop with DAB substrate and counterstain with hematoxylin

Critical controls:

• Positive control: Tissues known to express PPIG (ubiquitously expressed, but levels may vary)

• Negative control: Primary antibody omission

• Isotype control: Non-specific antibody of same isotype and concentration

When evaluating staining, researchers should focus on nuclear localization patterns, consistent with PPIG's reported localization to the nuclear matrix .

How can PPIG antibodies elucidate the protein's role in pre-mRNA splicing regulation?

PPIG's reported involvement in pre-mRNA splicing regulation can be investigated using several antibody-based approaches:

Protein interaction studies:

• Co-immunoprecipitation (Co-IP): Use PPIG antibodies to pull down protein complexes and identify splicing factors that interact with PPIG.

• Proximity ligation assay (PLA): Detect in situ interactions between PPIG and known splicing factors.

• GST-pulldown validation: Confirm interactions identified in Co-IP using recombinant proteins.

Localization studies:

• Immunofluorescence co-localization: Perform dual staining with PPIG antibodies and markers of nuclear speckles (SC35, SR proteins) to assess co-localization with splicing machinery.

• Subcellular fractionation: Use PPIG antibodies to track distribution between nucleoplasmic and chromatin-associated fractions during splicing events.

Functional validation:

• Splicing assays: Employ PPIG antibodies to monitor protein levels in knockdown/overexpression studies examining alternative splicing patterns.

• Chromatin immunoprecipitation (ChIP): Investigate whether PPIG associates with chromatin at specific splice sites.

• RNA immunoprecipitation (RIP): Use PPIG antibodies to identify RNA targets bound by PPIG.

Given PPIG's classification as a "CARS-cyclophilin" and "SR-cyclophilin" , its interactions with SR proteins (known splicing regulators) should be a focus of investigation.

What strategies should be employed for optimizing PPIG antibody performance in co-immunoprecipitation studies?

For successful co-immunoprecipitation (Co-IP) studies using PPIG antibodies, consider these methodological strategies:

Antibody selection:

• Choose antibodies validated for immunoprecipitation applications

• Select antibodies targeting epitopes unlikely to be involved in protein-protein interactions

• Consider using multiple antibodies against different PPIG epitopes to confirm results

Protocol optimization:

• Lysis buffer selection: Use gentle non-denaturing buffers (e.g., NP-40 or Triton X-100-based) that preserve native protein interactions

• Nuclear extraction: Since PPIG localizes to the nuclear matrix , specialized nuclear extraction protocols may be necessary

• Cross-linking consideration: Reversible protein cross-linking may stabilize transient interactions

• Pre-clearing: Incorporate a pre-clearing step with protein A/G beads to reduce non-specific binding

• Elution conditions: Optimize to maintain integrity of co-precipitated proteins

Critical controls:

• Input control: Save a small aliquot of pre-IP lysate to confirm starting material

• Isotype control: Perform parallel IP with isotype-matched non-specific antibody (e.g., normal rabbit IgG)

• Reverse Co-IP: Validate interactions by immunoprecipitating suspected interaction partners and blotting for PPIG

• Specificity validation: Include PPIG-depleted lysates as negative controls

Additionally, consider the phosphorylation state of PPIG, as phosphorylation at sites like Ser376 may affect protein interactions. For studying phosphorylation-dependent interactions, parallel experiments with phospho-specific antibodies or phosphatase treatments may be informative.

What control samples are essential when validating new PPIG antibodies?

A comprehensive validation strategy for PPIG antibodies should include multiple control samples:

Positive controls:

• Recombinant protein: Purified full-length PPIG or the specific domain containing the antibody epitope

• Overexpression systems: Cells transiently transfected with PPIG expression constructs

• High-expression tissues/cells: Tissues or cell lines known to express high levels of PPIG

Negative controls:

• Knockout/knockdown samples: CRISPR/Cas9 PPIG knockout or siRNA knockdown cells

• Blocking peptides: Pre-incubation of antibody with immunogen peptide to demonstrate specificity

• Secondary-only controls: Omission of primary antibody to assess background signal

Application-specific controls:

• Western blot:

  • Size confirmation (expected at 110 kDa)

  • Multiple antibodies targeting different epitopes should detect same band

  • Dose-dependent signal with recombinant protein

• Immunohistochemistry/Immunofluorescence:

  • Isotype control antibodies

  • Known expression pattern comparison

  • Signal blocking with immunogen peptide

• Immunoprecipitation:

  • IgG control immunoprecipitations

  • Input sample analysis

  • Reverse immunoprecipitation

For phospho-specific PPIG antibodies , additional controls should include phosphatase-treated samples and stimulation conditions known to affect the phosphorylation site of interest.

How do polyclonal and monoclonal PPIG antibodies compare in research applications?

While most commercially available PPIG antibodies are polyclonal antibodies produced in rabbits , understanding the comparative advantages of polyclonal versus monoclonal antibodies is important for experimental design:

Polyclonal PPIG antibodies:

Advantages:

• Recognize multiple epitopes, potentially increasing detection sensitivity

• More tolerant of minor sample variations (fixation, protein denaturation)

• Often perform better for applications requiring native protein detection (IP)

• May maintain reactivity even if some epitopes are masked or modified

Limitations:

• Lot-to-lot variability requiring validation of each new lot

• Potential for higher background in some applications

• Finite supply from each immunized animal

Monoclonal PPIG antibodies:

Advantages:

• Consistent epitope recognition between lots

• Generally higher specificity for the target epitope

• Better for detecting specific post-translational modifications

• Superior for quantitative applications requiring reproducibility

Limitations:

• May lose reactivity if the single epitope is altered or masked

• Often less sensitive than polyclonal antibodies

• May perform poorly if the epitope is not accessible in native conformation

Application-specific selection considerations include using polyclonal antibodies for maximum sensitivity in Western blot and monoclonal antibodies for quantitative applications or detection of specific post-translational modifications, such as phosphorylation at Ser376 .

How can PPIG antibodies contribute to investigating disease mechanisms?

PPIG antibodies can serve as valuable tools for exploring potential roles of PPIG in disease pathways through several methodological approaches:

Expression analysis:

• Comparative tissue studies: Use immunohistochemistry with PPIG antibodies to compare expression levels between normal and diseased tissues

• Western blot quantification: Measure PPIG protein levels across disease stages or treatment conditions

• Tissue microarray screening: Screen multiple patient samples simultaneously for PPIG expression patterns

Functional investigations:

• Splicing dysregulation: Since PPIG is involved in pre-mRNA splicing , examine alternative splicing patterns in disease models while monitoring PPIG levels

• Post-translational modifications: Use phospho-specific antibodies to determine if PPIG phosphorylation state changes in disease contexts

• Protein-protein interactions: Compare PPIG interaction partners between normal and diseased states using co-immunoprecipitation

Validation of experimental models:

• Knockdown/overexpression validation: Confirm PPIG manipulation in disease models

• Rescue experiments: Verify restored PPIG levels following therapeutic interventions

• Mechanistic studies: Track PPIG localization changes in response to disease-relevant stressors